BMC Research Notes (Jul 2020)

Moderate rate of transmitted resistance mutations to antiretrovirals and genetic diversity in newly HIV-1 patients diagnosed in Benin

  • Edmond Tchiakpe,
  • Rene K. Keke,
  • Nicole Vidal,
  • Clément Ahoussinou,
  • Olga Sekpe,
  • Hermione G. Dagba,
  • Eric Gbaguidi,
  • Conrad Tonoukouen,
  • Aldric Afangnihoun,
  • Moussa Bachabi,
  • Flore A. Gangbo,
  • Halimatou Diop-Ndiaye,
  • Coumba Toure-Kane

DOI
https://doi.org/10.1186/s13104-020-05151-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Objective Seventeen years after the start of the IBAARV (Beninese initiative for access to antiretrovirals), transmitted drug resistance mutations in ARV-naïve patients and HIV-1 genetic diversity were investigated in Benin. Results Drug resistance mutations were detected in (27/248; 10.9%) according to the WHO SDRM 2009 list, with a predominance of mutations directed against NNRTIs drugs (24/248; 10%). Phylogenetic and recombination analyses showed a predominance of CRF02_AG strains (165/248; 66.5%) and a high genetic diversity with five other variants and 39 URFs (15.7%) which contained portions of strains that co-circulate in Benin. Eight recent transmission chains revealed active ongoing transmission of HIV-1 strains among ARV-naïve patients. Our study showed a moderate primary drug resistance mutations rate and also provided recent data on the HIV-1 variants that circulate in Benin. Regular monitoring of primary drug resistance is required to adapt HIV-1 treatment strategies and adoption of new WHO recommendations in Benin.

Keywords